Compare PCVX & GNRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | GNRC |
|---|---|---|
| Founded | 2013 | 1959 |
| Country | United States | United States |
| Employees | N/A | 9400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 11.8B |
| IPO Year | 2020 | N/A |
| Metric | PCVX | GNRC |
|---|---|---|
| Price | $54.62 | $209.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 18 |
| Target Price | $98.33 | ★ $198.88 |
| AVG Volume (30 Days) | ★ 1.1M | 819.1K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.43 |
| Revenue Next Year | N/A | $11.77 |
| P/E Ratio | ★ N/A | $84.89 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $104.90 |
| 52 Week High | $73.82 | $241.09 |
| Indicator | PCVX | GNRC |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 53.51 |
| Support Level | $42.30 | $195.41 |
| Resistance Level | $56.04 | $238.55 |
| Average True Range (ATR) | 2.36 | 8.58 |
| MACD | -0.59 | -2.21 |
| Stochastic Oscillator | 21.90 | 50.82 |
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.